NEW YORK--(BUSINESS WIRE)--Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors. Dr. Herbert joins as the company announces the launch of a novel drug development program supporting ovarian health throughout a women’s lifespan adding to their next generation of interventions and advancements in women’s health.
Dr. Herbert brings more than 30 years of biopharma industry experience within R&D, business development and Corporate strategy along with unique insights gained heading the investment committee of MVentures. She most recently served as Senior Vice President, Head of Strategic Excellence at Merck Group (Merck KGAa) with global responsibility for Merck’s Healthcare strategy, portfolio management, strategy realisation and global insights teams. Prior to this she was is member of the Executive board of Merck Serono, the Biopharma arm of Merck KGAa, heading up Business Development including responsibility for the Venture investing team. She has previously served as Corporate Vice President, Head of Reproductive Health & Metabolic Endocrinology Global Product Development at Serono Pharmaceuticals.
Dr. Piraye Yurttas Beim, Celmatix Founder and CEO commented, “We are honored to have someone with Dr. Herbert’s experience and success in biopharma join our Strategic Advisory Board. Not only does Dr. Herbert have an incredible wealth of knowledge in R&D and pre-clinical work, but her accomplishments in licensing are also known throughout the industry and speak to her drive and understanding of biopharma. We now are elated she will be able to apply these same insights to our work at Celmatix.”
Dr. Herbert commented, “I am delighted to be joining the Advisory Board of Celmatix to support the development and growth of the company as they advance their unique pipeline towards the clinic. There has never been more at stake for women’s health and we are at the cusp of a new era in drug development. The work that Celmatix is doing in ovarian health has the potential to improve the lives of women worldwide. I look forward hugely to working with them to bring to these millions of women the much needed new precision medicine therapies for important conditions such as endometriosis, PCOS and infertility.”
Dr. Herbert received her B.Sc. Honors, MSc. and Ph.D. degrees in Biochemistry from the University of Manchester in the United Kingdom.
Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology.
With a pipeline focused on prevalent and debilitating conditions like polycystic ovary syndrome (PCOS), endometriosis, infertility, and premature menopause, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies.
For more information, visit the company’s website at www.celmatix.com